Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CHU de Quebec-Universite Laval
With
Canadian Glaucoma Clinical Research Council
Pfizer
The selective laser trabeculoplasty (SLT) is the laser treatment of choice for treating glaucoma. A There is however a controversy regarding the use of drops post-treatment. Indeed, some would prefer not to pharmacologically modulate the post-op inflammatory response which can be an integral part of the treatment by favouring the mobilisation of the macrophages which participate to the trabeculae "cleaning". Others will prefer to calm the inflammatory reaction and choose an anti-inflammatory drug (either steroidal or non-steroidal).
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients suffering from with primary open-angle glaucoma.
Patients with IOP \> 21 mmHg, uncontrolled with medical treatment or due to non-compliance, or to whom this is the first glaucoma treatment.
Patients \> 18 years old, able to consent.
Patients consenting to the trial.
You may not be if
Patients suffering from chronic glaucoma other than primary open-angle glaucoma
Patients who had changes done to their anti-glaucoma treatments over the last 6 weeks or following the SLT
Patients under oral corticosteroid treatment at the time of the operation or those who have stopped during the preceding month.
Patients suffering from an important corneal disease which interferes with the capacity to visualize the entire trabeculae.
Monophthalmic patients.
Patients who already underwent a glaucoma treatment to the eye requiring treatment.
Patients who already underwent a glaucoma treatment using SLT or ALT (Argon laser trabeculoplasty)
Patients who underwent cataract surgery in the past 3 months.
Pregnant patients.
Clareo Health | Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma
